Tesamorelin: can it really shrink stubborn belly fat?

Tesamorelin is a lab-made version of the hormone that tells your pituitary gland to release growth hormone. As Egrifta WR, it's FDA-approved for one use: reducing excess belly fat in adults with HIV who have lipodystrophy, where large trials showed it shrinks deep belly fat. Any other use, such as healthy aging, is off-label and unproven. A physician can help you lose belly fat with options tested in people.

Reviewed by Darshan Patel, MD, Obesity medicine physician, on 2026-11-12. Next review 2026-12-12.

Book my consultation Video consultations with an Aayu Well physician. Most major insurance accepted, plus convenient cash pay options.

Why people are curious about tesamorelin

Belly fat that won't budge is frustrating, and tesamorelin comes up online as a way to target it and as a healthy-aging peptide. Unlike most peptides you'll read about, it's a real FDA-approved medicine, which makes it sound like a safe bet. It works by prompting your pituitary gland to release more of your own growth hormone. The catch is that it was approved for one specific group of people.

Losing belly fat is a great goal, and a healthy one. The real question is whether tesamorelin is the best way for you to get there.

What the research shows so far

Evidence grade C for the uses people ask about online. For its approved use, the evidence is much stronger. How we grade evidence.

• In adults with HIV and excess belly fat: in a 26-week trial of 412 people, deep belly fat (the visceral fat around the organs) fell about 15% on tesamorelin and rose 5% on placebo, and triglycerides improved. Its label reports two trials of about 400 people each. When people switched to placebo after 26 weeks, their deep belly fat went back up over the next six months.
• In adults with HIV and fatty liver: in a year-long trial of 61 people, liver fat fell more on tesamorelin than on placebo.
• In adults without HIV: one year-long trial of 60 adults with abdominal obesity and low growth hormone found less deep belly fat and lower triglycerides than placebo, with no change in blood sugar. That's a small group, and it isn't an approved use.
• Still open: long-term heart safety, and whether it helps healthy aging, muscle or energy in people without HIV.

Your goal, with stronger evidence behind it

Most people who ask about tesamorelin want less belly fat and a healthier, stronger body. Here's what has been tested in people.

• Lose belly fat by losing weight you can keep off. Tesamorelin's label calls it weight neutral. For people living with obesity, GLP-1 medicines such as semaglutide and tirzepatide have been tested in large trials with thousands of adults. They led to far more weight loss than placebo and improved heart and metabolic health numbers.
• A healthier liver. In a year-long study of 293 people with fatty liver inflammation, 90% of those who lost at least 10% of their weight saw the inflammation resolve.
• Keep your muscle while you lose fat. In a 6-month trial of 160 older adults losing weight, those who added strength training lost less muscle than those who only did aerobic exercise. At Aayu Well, a registered dietitian helps you build meals that support your muscle as the weight comes off.

Aayu Elevate™ puts this together: video visits with an obesity medicine physician, a registered dietitian, and medicine when it's right for you. Most major insurance accepted, plus convenient cash pay options. Book my consultation

Is tesamorelin legal now?

Yes, as a prescription medicine. Egrifta WR is FDA-approved to reduce excess belly fat in adults with HIV who have lipodystrophy. Physicians may prescribe an approved drug for other uses when they judge it medically appropriate, but that's off-label: FDA hasn't found it safe and effective for those uses.

Tesamorelin isn't one of the six peptides in the October 2026 HHS policy, and that policy doesn't cover peptides outside its list. Egrifta moved to FDA's biologics rules on March 23, 2020, and FDA has said products that moved then aren't eligible for the exemptions that let pharmacies compound drugs. Tesamorelin sold as a compounded or research product isn't Egrifta and hasn't been through FDA review. See which peptides can be compounded.

Good to know before you try it

• Its label says long-term heart safety hasn't been established, and it isn't meant for weight loss.
• It can raise blood sugar, so blood sugar is checked first, and people with diabetes are monitored.
• It can cause fluid retention, with swelling, joint pain or carpal tunnel. The most common side effects include joint pain, redness and itching where it's injected, limb pain, swelling and muscle aches.
• It raises IGF-1, a growth factor. It isn't used with active cancer or in pregnancy.
• It's banned in sport at all times, so athletes who are drug tested should skip it.
• Products labeled research use only aren't made or tested for people. Here's why that label matters.

Where Aayu Well stands

We don't prescribe tesamorelin right now. We're following the research closely, and we review this page every month.

What we can help with today is usually what sits behind the question: weight, belly fat, blood sugar, energy, sleep and mood. Bring your peptide questions to your first visit. Your physician will give you a straight answer and a plan built around you.

Questions people ask

Can I talk to an Aayu Well physician about peptides?

Yes, and we'd encourage it. Bring your questions to your visit. We don't prescribe tesamorelin right now, but your physician will go over the evidence with you, review everything you take, and build a plan for the goal behind the question, whether that's belly fat, weight, energy or sleep.

Is tesamorelin FDA-approved?

Yes, for one use. As Egrifta WR, it's approved to reduce excess abdominal fat in adults with HIV who have lipodystrophy. Physicians may prescribe an approved drug for other uses when they judge it appropriate, but FDA hasn't found it safe and effective for those uses. Compounded tesamorelin is not FDA-approved.

Will tesamorelin help me lose weight?

Not by itself. Its label says it isn't for weight loss because it doesn't change weight. It targets deep belly fat. If weight is the goal, other medicines have been tested for exactly that.

Is tesamorelin safe?

For its approved use, its label lists known risks: higher blood sugar, fluid retention with swelling, joint pain or carpal tunnel, allergic reactions and injection-site reactions. It raises IGF-1, a growth factor, and it isn't used with active cancer or in pregnancy. Long-term heart safety hasn't been established.

Can I take it with a GLP-1 like Wegovy or Zepbound?

We haven't found studies of the two together, and tesamorelin can raise blood sugar, so it's worth a conversation first. Tell the physician who prescribes your GLP-1 about any peptide you use.

Is tesamorelin banned in sports?

Yes. The World Anti-Doping Agency's 2026 list prohibits it at all times, in and out of competition, so athletes who are drug tested should skip it.

Sources

1. EGRIFTA WR (tesamorelin for injection) prescribing information, BLA 022505, DailyMed (updated July 29, 2026)
2. FDA: Notice to compounders, changes that affect compounding as of March 23, 2020
3. RAPS: Government spending bill tweak means 3 more NDAs will transition to BLAs, including Egrifta (January 15, 2020)
4. Federal Register notice FR Doc. 2026-22192, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (October 30, 2026)
5. Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (November 4, 2026)
6. FDA: Understanding unapproved use of approved drugs off label
7. FDA: Compounding and the FDA, questions and answers
8. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
9. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
10. Makimura H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779.
11. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
12. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
13. Villareal DT, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376(20):1943-1955.
14. Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.
15. German Sport University Cologne: WADA 2026 Prohibited List, S2 peptide hormones, growth factors, related substances and mimetics